Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Equa Gets Go-Ahead for Additional Concurrent-Use Indications of Insulin and Other Hypoglycemic Agents: PAFSC 1st Committee
February 8, 2013
- PAFSC First Committee Recommends Approval for Japan’s First FD Treatment Acofide
February 8, 2013
- Health Sciences Council to Upgrade Committee on Immunization to “Department on Preventive Vaccination and Vaccines”
February 7, 2013
- NIHS to Accelerate Medical Innovation Research
February 7, 2013
- MHLW to Launch Panel on Feb. 14 to Set New Rules for Online OTC Drug Sales
February 6, 2013
- New Council on Conflicts of Interest Holds 1st Meeting, Some Doctors Say Disclosure of Individual Payments, Recipient Names “Hasty”
February 5, 2013
- Takeda, KAKETSUKEN Apply for Funding Under Second Project to Develop and Manufacture New Flu Vaccines
February 4, 2013
- PAFSC's 2nd Committee Recommends Approval for Arzerra
February 1, 2013
- CRO Association to Compile Guidelines for Third-Party Outsourcing after GCP Revision
February 1, 2013
- Government Allocates 9 Billion Yen in FY2013 Budget to Boost Reviews and Safety Measures of Pharmaceutical Products
January 31, 2013
- Japan Cabinet OKs FY2013 Budget, Social Security Outlays Nearly 29 Trillion Yen
January 30, 2013
- 13 Generic Makers Slapped with Improvement Order due to South Korean Supplier’s GMP Violation
January 30, 2013
- Membership of Committee on Non-Prescription Drugs to Be Evenly Split Between Medical, Pharmaceutical Communities
January 30, 2013
- Ordinary Diet Session Convenes; Bills to Amend Preventive Vaccination Law, Public Assistance Law Expected to Be Submitted
January 30, 2013
- Welfare Recipients Will Be Required to Use Generics from April 1; Those Who Request Original Drugs Will Be Asked to Give Reason
January 29, 2013
- Ministers of Health, Finance, and Internal Affairs Agree to Add 3 Vaccines to Public Vaccination Programs in April
January 29, 2013
- PAFSC First Committee on New Drugs to Discuss Approval of Japan’s First FD Treatment
January 28, 2013
- Preliminary Meetings of Regulatory Consultations Reach 331, Increase Found in Central and Peripheral Nervous System Drugs
January 25, 2013
- New Government Economic Panel Holds First Meeting, Takeda President Hasegawa Proposes to Bring Competition to Medical Industry
January 25, 2013
- Premium for New Drug Development to Be Discussed Alongside Long-Listed Drugs, Development of Drugs Used Off-Label: Health Minister Tamura
January 25, 2013
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…